Study of EV for Recurrent Endometrial Carcinoma

Summary

This study is testing a drug called enfortumab vedotin in up to 12 patients with advanced endometrial (uterine) cancer that has worsened after previous treatments, including immunotherapy. The goal is to see how well the drug works and how safe it is. Patients will be treated for up to one year and followed over time to monitor their health and response to the treatment.

Timeline

Start

2026-07-10

Primary completion

2027-11-30

Completion

2028-05-31

Drugs

Indications